Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

Not specified

Study Completion Date

April 30, 1998

Conditions
Toxoplasmosis, CerebralHIV Infections
Interventions
DRUG

Sulfadiazine

DRUG

Clarithromycin

DRUG

Atovaquone

DRUG

Pyrimethamine

DRUG

Leucovorin calcium

Trial Locations (16)

10003

Beth Israel Med. Ctr. (Mt. Sinai), New York

13210

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

21287

Johns Hopkins Adult AIDS CRS, Baltimore

46202

Methodist Hosp. of Indiana, Indianapolis

60611

Northwestern University CRS, Chicago

60612

Cook County Hosp. CORE Ctr., Chicago

63110

Washington U CRS, St Louis

96816

Queens Med. Ctr., Honolulu

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

331361013

Univ. of Miami AIDS CRS, Miami

432101228

The Ohio State Univ. AIDS CRS, Columbus

452670405

Univ. of Cincinnati CRS, Cincinnati

462025250

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

900331079

USC CRS, Los Angeles

Unknown

St. Louis ConnectCare, Infectious Diseases Clinic, St Louis

NY Univ. HIV/AIDS CRS, New York

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH